血清脂联素与慢性阻塞性肺疾病的研究进展被引量：2

导出

摘要 COPD是一种可以预防和可以治疗的常见疾病,其特征是持续存在的气流受限,气流受限呈进行性发展,伴有气道和肺对有害颗粒或气体所致慢性炎症反应的增加[1].目前许多研究表明在COPD发病机制中细胞因子具有重要的作用.血清脂联素是主要由脂肪细胞产生的一种细胞因子,在脂代谢、胰岛素抵抗、心血管系统等中具有重要的作用.随着研究的不断深入,其与炎症性疾病等相关疾病的关系逐步被认识,有研究认为脂联素参与了COPD 的气道炎性反应, 是一种COPD 气道炎症新的标志物.现仅就脂联素与COPD的相关性进行综述.

作者任小花顾玉海

机构地区青海大学医学院青海省人民医院

出处《临床肺科杂志》 2014年第2期334-336,共3页 Journal of Clinical Pulmonary Medicine

关键词慢性阻塞性肺疾病血清脂联素 COPD 慢性炎症反应气道炎症气流受限细胞因子胰岛素抵抗

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献20

1蔡柏蔷.放至全球而皆准的策略——我看《GOLD颁布的COPD全球策略(2011年修订版)》[J].中国实用内科杂志,2012,32(5):351-355. 被引量：64
2Scherer PE, Willia S, Fogliano M, et al. A novel serum protein sim- ilar to Clq,produced exclusively in adipocytes[ J]. J Biol Chem, 1995,270(45 ) :26746 - 26749.
3Pajvani UB,Du X,Combs TP,et al. Structure -function studies of the adipocyte - secreted hormone Acrp30/adiponectin. Implica- tions fpr metabolicregulation and bioactivity [ J ]. J Biol Chem, 2003,278( 11 ) :9073 -85.
4Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects [ J ]. Nature,2003,423 (6941) :762 -769.
5Hug C, Wang J, Ahmad NS, et al. T - cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponec- tin[J]. Proc Natl Acad Sci USA, 2004, 101 (28):10308 - 10313.
6张艳,魏文青,焦娟,刘晶,杨梦迪.脂联素的生物学功能研究进展[J].中国热带医学,2013,13(5):649-650. 被引量：12
7Bianco A, Mazzarella G, Turchiarelli V, et al. Adiponectin: an attractive marker for metabolic disorders in Chronic Obstructive Pulmonary Disease (COPD) [ J]. Nutrients, 2013,5 ( 10 ) :4115 -25.
8Yuan Y, Jiang H, Kuang J,et al. Genetic variations in ADIPOQgene are associated with chronic obstructive pulmonary disease [ J ]. PLoS One, 2012 , 7 ( 11 ) : e50848.
9Sull JW, Kim H J, Yun JE, et al. Serum adiponect in is associated with smoking status in healthy Korean men [ J ]. Endocr J, 2009, 56:73 -78.
10白学礼,许建英.吸烟对大鼠血清瘦素、脂联素、IL-6和C反应蛋白的影响[J].中国呼吸与危重监护杂志,2010,9(3):298-300. 被引量：10

二级参考文献33

1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8251
2van Weel C, Schellevis FG. Comorbidity and guidelines:conflicting interests. Lancet, 2006,367:550 -551.
3Sin DD,Anthonisen NR,Soriano JB, et al. Mortality in COPD: Role of comorbidities. Eur Respir J ,2006,28 : 1245-1257.
4Schols AM, Creutzerg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1999,160 : 1220-1226.
5Kirdar S, Setter M, Ceylan E, et al. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest,2009,69:219-224.
6Chen H, Hansen MJ, Jones JE, et al. Long-term cigarette smoke exposure increases uncoupling protein expression but reduces energy intake. Brain Res,2008,1228 : 81-88.
7Hotta Y, Yatsuya H, Toyoshima H, et al. Low leptin but high insulin resistance of smokers in Japanese men. Diabetes Res Clin Pract, 2008,81:358-364.
8Sull JW, Kin, H J, Yun JE, et al. Serum adiponectin is associated with smoking status in healthy Korean men. Endocr J ,2009,56:73-78.
9Kirchgessner TG, Uysal KT, Wiesbrock SM, et al. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest, 1997,100: 2777 -2782.
10Trujillo ME, Sullivan S, Harten I, et al. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab ,2004 ,89 :5577-5582.